Naronapride
- Generic Name
- Naronapride
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H41ClN4O5
- CAS Number
- 860174-12-5
- Unique Ingredient Identifier
- 058896B00B
- Indication
Investigated for use/treatment in gastroesophageal reflux disease (GERD) and gastroparesis.
- Associated Conditions
- -
- Associated Therapies
- -
Relief Therapeutics provides update on potential transaction with Renexxion
Relief Therapeutics and Renexxion are advancing their reverse merger, aiming for a definitive agreement by Q1 2025, focusing on long-term success and shareholder value, despite no guarantees of completion.
Relief Therapeutics Provides Update on Potential Transaction with Renexxion
Relief Therapeutics and Renexxion are advancing towards a reverse merger, aiming to sign a definitive agreement by Q1 2025, focusing on long-term success and shareholder value.
Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger
Relief Therapeutics and Renexxion sign non-binding LOI for reverse merger to create a combined entity with an expanded therapeutic pipeline, aiming to strengthen competitive position, enhance shareholder value, and accelerate delivery of innovative therapies.
Related Clinical Trials:
An update on prucalopride in the treatment of chronic constipation
Chronic constipation (CC) significantly impacts quality of life, with initial treatments often unsatisfactory. Prucalopride, a selective 5-HT4 receptor agonist, has shown efficacy in short-term relief of CC symptoms without cardiac side effects, approved in several countries but not the US. Long-term efficacy and benefits in specific populations remain under investigation.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath